CompletedPhase 1NCT00562380

AMG-479 in Treating Patients With Advanced Solid Tumors or Non-Hodgkin Lymphoma

Studying Acute lymphoblastic leukemia

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Amgen
Principal Investigator
Mace L. Rothenberg, MD, FACP
Vanderbilt-Ingram Cancer Center
Intervention
ganitumab(biological)
Enrollment
64 enrolled
Eligibility
18 years · All sexes
Timeline
20052010

Study locations (1)

Collaborators

National Cancer Institute (NCI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00562380 on ClinicalTrials.gov

Other trials for Acute lymphoblastic leukemia

Additional recruiting or active studies for the same condition.

See all trials for Acute lymphoblastic leukemia

← Back to all trials